96-19507. CIBA Vision Corp.; Premarket Approval of SOLO-care brand MULTI- PURPOSE SOLUTION  

  • [Federal Register Volume 61, Number 148 (Wednesday, July 31, 1996)]
    [Notices]
    [Pages 39977-39978]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 96-19507]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Food and Drug Administration
    [Docket No. 96M-0254]
    
    
    CIBA Vision Corp.; Premarket Approval of SOLO-care brand MULTI-
    PURPOSE SOLUTION
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is announcing its 
    approval of the application by CIBA Vision Corp., Duluth, GA, for 
    premarket approval, under the Federal Food, Drug, and Cosmetic Act (the 
    act), of SOLO-care brand MULTI-PURPOSE SOLUTION. FDA's Center for 
    Devices and Radiological Health (CDRH) notified the applicant, by 
    letter of April 25, 1996, of the approval of the application.
    
    DATES: Petitions for administrative review by August 30, 1996.
    
    ADDRESSES: Written requests for copies of the summary of safety and 
    effectiveness data and petitions for administrative review to the 
    Dockets Management Branch (HFA-305), Food and Drug Administration, 
    12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.
    
    FOR FURTHER INFORMATION CONTACT: James F. Saviola, Center for Devices 
    and Radiological Health (HFZ-460), Food and Drug Administration, 9200 
    Corporate Blvd., Rockville, MD 20850, 301-594-1744.
    
    SUPPLEMENTARY INFORMATION: On December 22, 1994, CIBA Vision Corp., 
    Duluth, GA 30136-1518, submitted to CDRH an application for premarket 
    approval of the SOLO-care brand MULTI-PURPOSE SOLUTION. The device is a 
    cleaning, rinsing, disinfecting, and storing solution and is indicated 
    for cleaning, rinsing, disinfecting, and storing soft (hydrophilic) 
    contact lenses and for dissolving enzyme tablets.
        -In accordance with the provisions of section 515(c)(2) of the act 
    (21 U.S.C.
    
    [[Page 39978]]
    
    360e(c)(2)) as amended by the Safe Medical Devices Act of 1990, this 
    premarket approval application (PMA) was not referred to the Ophthalmic 
    Devices Panel of the Medical Devices Advisory Committee, an FDA 
    advisory committee, for review and recommendation because the 
    information in the PMA substantially duplicates information previously 
    reviewed by this panel.
        -On April 25, 1996, CDRH approved the application by a letter to 
    the applicant from the Director of the Office of Device Evaluation, 
    CDRH.
        -A summary of the safety and effectiveness data on which CDRH based 
    its approval is on file in the Dockets Management Branch (address 
    above) and is available from that office upon written request. Requests 
    should be identified with the name of the device and the docket number 
    found in brackets in the heading of this document.
    
    Opportunity for Administrative Review
    
        -Section 515(d)(3) of the act authorizes any interested person to 
    petition, under section 515(g) of the act, for administrative review of 
    CDRH's decision to approve this application. A petitioner may request 
    either a formal hearing under part 12 (21 CFR part 12) of FDA's 
    administrative practices and procedures regulations or a review of the 
    application and CDRH's action by an independent advisory committee of 
    experts. A petition is to be in the form of a petition for 
    reconsideration under Sec. 10.33(b) (21 CFR 10.33(b)). A petitioner 
    shall identify the form of review requested (hearing or independent 
    advisory committee) and shall submit with the petition supporting data 
    and information showing that there is a genuine and substantial issue 
    of material fact for resolution through administrative review. After 
    reviewing the petition, FDA will decide whether to grant or deny the 
    petition and will publish a notice of its decision in the Federal 
    Register. If FDA grants the petition, the notice will state the issue 
    to be reviewed, the form of review to be used, the persons who may 
    participate in the review, the time and place where the review will 
    occur, and other details.
        -Petitioners may, at any time on or before August 30, 1996, file 
    with the Dockets Management Branch (address above) two copies of each 
    petition and supporting data and information, identified with the name 
    of the device and the docket number found in brackets in the heading of 
    this document. Received petitions may be seen in the office above 
    between 9 a.m. and 4 p.m., Monday through Friday.
        -This notice is issued under the Federal Food, Drug, and Cosmetic 
    Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under 
    authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) 
    and redelegated to the Director, Center for Devices and Radiological 
    Health (21 CFR 5.53).
    
        Dated: June 5, 1996.
    Joseph A. Levitt,
    Deputy Director for Regulations Policy, Center for Devices and 
    Radiological Health.
    [FR Doc. 96-19507 Filed 7-30-96; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
07/31/1996
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
96-19507
Dates:
Petitions for administrative review by August 30, 1996.
Pages:
39977-39978 (2 pages)
Docket Numbers:
Docket No. 96M-0254
PDF File:
96-19507.pdf